Research Topics
| David B AgusSummaryAffiliation: Cedars-Sinai Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Ductal adenocarcinoma of the prostateRonald L Shazer
Louis Warschaw Prostate Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Clin Adv Hematol Oncol 2:393-5; discussion 396. 2004- Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapyDavid B Agus
Cedars Sinai Prostate Cancer Center, Los Angeles, CA 90048, USA
J Clin Oncol 25:675-81. 2007..The aim of this single-arm phase II clinical study was to assess the efficacy and safety of single-agent pertuzumab in castration-resistant prostate cancer (CRPC) patients who had experienced progression after prior chemotherapy... - Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerDavid B Agus
Cedars Sinai Prostate Cancer Center and Medical Center, Los Angeles, CA 90048, USA
J Clin Oncol 23:2534-43. 2005..A clinical study was conducted to investigate safety and pharmacokinetics of pertuzumab and to perform a preliminary assessment of HER dimerization inhibition as a treatment strategy... - Update on HER-kinase-directed therapy in prostate cancerMitchell E Gross
Louis Warschaw Prostate Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Clin Adv Hematol Oncol 2:53-6, 64. 2004..These include antibodies, tyrosine kinase inhibitors, and novel strategies which seek to decrease HER2 expression... 
HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferationAnjali Jain
Sumner M Redstone Prostate Cancer Research Program, Cedars Sinai Medical Center, Los Angeles, California, USA
Cancer Res 70:1989-99. 2010..Furthermore, EGFR kinase inhibition induces HER kinase receptors to engage in alternative dimerization that can ultimately influence therapeutic selection and responsiveness...
Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signalingSheldon R Mink
Louis Warschaw Prostate Cancer Center, Sumner M Redstone Prostate Cancer Research Program, Cedars Sinai Medical Center, Los Angeles, California, USA
Prostate 70:1201-10. 2010..In this study, we explore an interaction between beta2M expression, prostate cancer tissue, and the androgen signaling axis...- Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanesShannon M Mumenthaler
Sumner M Redstone Prostate Cancer Research Program, Cedars Sinai Medical Center, Los Angeles, CA, USA
Mol Cancer Ther 8:2882-93. 2009..These findings support the idea that inhibiting Pim kinases, in combination with a chemotherapeutic agent, could play an important role in prostate cancer treatment by targeting the clinical problem of chemoresistance... - 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growthNoriyuki Takai
Division of Hematology/Oncology, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA 90048, USA
Cancer 104:2701-8. 2005..The response appears limited to lines in which HER2 heterodimers were able to transduce proliferative signals. Our findings suggest a strong rationale to conduct clinical trials of 2C4 in a subset of patients with ovarian tumors... - Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trialRonald L Shazer
Louis Warschaw Prostate Cancer Center, Cedars-Sinai Medical Center, 8631 West Third Street, Los Angeles, CA 90048, USA
BJU Int 97:691-7. 2006..Drug related toxicity was minimal. CONCLUSION: Raloxifene has activity in xenograft models, slowing disease progression. This translated to possible disease stabilization in patients with AIPC. Further studies are warranted... - Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgammaMichael Hedvat
Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, 8631 West Third Street, Suite 1001E, Los Angeles, CA 90048, USA
Cancer Cell 5:565-74. 2004..This study introduces a novel concept of an in vivo crosstalk between the HER-kinase axis and PPARgamma pathways, ultimately leading to negative regulation of PPARgamma activity and tumor growth inhibition... - Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancerWilliam D Fox
Cedars-Sinai Prostate Cancer Center, Los Angeles, California 90048, USA
Clin Cancer Res 8:3226-31. 2002..CONCLUSIONS: rhu alpha VEGF has cytostatic clinical activity in this androgen-independent prostate cancer xenograft model, and the addition of paclitaxel demonstrates increased clinical activity... - CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenograftsAnna V Galkin
Cedars-Sinai Louis Warschaw Prostate Cancer Center, Los Angeles, California 90045, USA
Prostate 61:228-35. 2004..CONCLUSIONS: These results identify CVS-3983 as a potent inhibitor of AI prostate cancer cell invasion in vitro and established xenograft tumor growth in vivo... 
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancerMitchell Gross
Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
BMC Cancer 7:142. 2007..Erlotinib is a specific inhibitor of the tyrosine-kinase activity of EGFR. The goal of this study is to determine the anti-cancer activity docetaxel combined with erlotinib for the treatment of elderly subjects with AIPC...- Epithelial membrane protein-1 is a biomarker of gefitinib resistanceAnjali Jain
Louis Warschaw Prostate Cancer Center, Los Angeles, CA 90048, USA
Proc Natl Acad Sci U S A 102:11858-63. 2005..This report suggests the role of the adhesion molecule, EMP-1, as a biomarker of gefitinib clinical resistance, and further suggests a probable cross-talk between this molecule and the EGFR signaling pathway... - Targeting the HER-kinase axis in cancerMitchell E Gross
Louis Warschaw Prostate Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Semin Oncol 31:9-20. 2004..This review focuses on the basic biology underlying HER-kinase pathway activation and the current state of development for agents that target this axis. In particular, the importance of pan-HER inhibitors is discussed... - Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancerShannon M Mumenthaler
Center for Applied Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
Mol Pharm 8:2069-79. 2011.... - PPARgamma signaling: one size fits all?Anjali Jain
Louis Warschaw Prostate Cancer Center, Cedars Sinai Prostate Cancer Center, Los Angeles, California 90048, USA
Cell Cycle 3:1352-4. 2004..Outcome of PPARgamma activation in cancer cells is not one-dimensional. PPARgamma signaling is dependent upon PPARgamma ligand affinity and binding characteristics, target cell context and interacting signaling networks... - Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growthDavid B Agus
Cedars-Sinai Prostate Cancer Center, Los Angeles, California 90048, USA
Cancer Cell 2:127-37. 2002..We demonstrate that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment... - Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibitionKian Kani
University of Southern California, Los Angeles, CA 90033, USA
Mol Cancer Ther 11:1071-81. 2012..In doing so, we also were able to identify which proteins might be useful as markers for monitoring response and which proteins might be useful as markers for a priori prediction of response... - Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIsSheldon R Mink
Cedars Sinai Medical Center, 8700 Beverly Boulevard, Davis 6012, Los Angeles, CA 90048, USA
Mol Cancer Res 8:809-20. 2010..This is the first demonstration that the tumor stroma is modified with acquisition of EGFR-TKI resistance and that it further contributes in promoting drug resistance... - Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discoveryImelda E deVera
Center for Applied Molecular Medicine at Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Clin Adv Hematol Oncol 4:541-9. 2006..Particular emphasis is placed on those aspects strongly associated with reproducibility from both clinical and laboratory perspectives... - A perspective on protein profiling of bloodJonathan E Katz
Louis Warschaw Prostate Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
BJU Int 96:477-82. 2005 - Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and copingKysa M Christie
Department of Psychology, University of Southern California, Los Angeles, CA 90089, USA
Psychooncology 18:508-14. 2009..We further predicted that cognitive processing, coping, and patient understanding of treatment options would mediate this association... - Precursor-ion mass re-estimation improves peptide identification on hybrid instrumentsRoland Luethy
Spielberg Family Center for Applied Proteomics, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
J Proteome Res 7:4031-9. 2008..These results demonstrate integration of msPrefix into traditional shotgun proteomics workflows significantly improves identification results... - TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cellsSigal Gery
Division of Hematology Oncology, Cedars Sinai Medical Center, Los Angeles, California, CA 90048, USA
Oncogene 21:4739-46. 2002.... - The current state of preclinical prostate cancer animal modelsKenneth J Pienta
University of Michigan, Department of Internal Medicine, Ann Arbor, MI, USA
Prostate 68:629-39. 2008..It should be possible to apply the knowledge gained molecular and epigenetic studies to develop new cell lines and models that mimic progressive and fatal prostate cancer and ultimately improve interventions... - Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapseSusan M Henshall
Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, Darlinghurst, Sydney, New South Wales 2010, Australia
Cancer Res 63:4196-203. 2003.... - 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenograftsDavid B Solit
Program in Cell Biology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 8:986-93. 2002..These results suggest that this drug may represent a new strategy for the treatment of prostate cancer...